Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite the fact that a variety of nuclear-encoded RNA-binding proteins (RBPs) are targeted to the chloroplast and play essential roles during post-transcriptional RNA metabolism in the chloroplast, the physiological roles of the majority of chloroplast-targeted RBPs remain elusive. Here, we investigated the functional role of a nuclear-encoded S1 domain-containing RBP, designated SDP, in the growth and development of Arabidopsis thaliana. Confocal analysis of the SDP-green fluorescent protein revealed that SDP was localized to the chloroplast. The loss-of-function sdp mutant displayed retarded seed germination and pale-green phenotypes, and grew smaller than the wild-type plants. Chlorophyll a content and photosynthetic activity of the sdp mutant were much lower than those of wild-type plants, and the structures of the chloroplast and the prolamellar body were abnormal in the sdp mutant. The processing of rRNAs in the chloroplast was defective in the sdp mutant, and SDP was able to bind chloroplast 23S, 16S, 5S and 4.5S rRNAs. Notably, SDP possesses RNA chaperone activity. Transcript levels of the nuclear genes involved in chlorophyll biosynthesis were altered in the sdp mutant. Collectively, these results suggest that chloroplast-targeted SDP harboring RNA chaperone activity affects rRNA processing, chloroplast biogenesis and photosynthetic activity, which is crucial for normal growth of Arabidopsis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/tpj.12889DOI Listing

Publication Analysis

Top Keywords

sdp mutant
20
sdp
10
chloroplast
8
rrna processing
8
crucial normal
8
normal growth
8
growth arabidopsis
8
arabidopsis thaliana
8
wild-type plants
8
photosynthetic activity
8

Similar Publications

Purpose Of Review: Advancements in precision medicine have shifted the treatment paradigm of brain metastases (BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more effective treatment of BM.

Recent Findings: In NSCLC, therapies such as osimertinib have improved efficacy in treating EGFR-mutant BM, with emerging combinations such as amivantamab and lazertinib offering promising alternatives for patients resistant to frontline therapies.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates the effectiveness of normalized apparent diffusion coefficient (nADC) versus percentage T2-FLAIR mismatch-volume (%T2FM-volume) in distinguishing IDH-mutant astrocytoma from other glioma types.* -
  • The analysis involved 105 non-enhancing gliomas, utilizing T2-FLAIR digital subtraction maps to identify tumor subregions, yielding results that showed nADC was significantly higher in IDH-mutant astrocytomas compared to other glioma subtypes.* -
  • Overall, nADC was found to be a more reliable classifier than %T2FM-volume, demonstrating higher sensitivity and specificity in identifying IDH-mutant astrocytomas, while survival analysis results indicated a trend
View Article and Find Full Text PDF

Background: While REIMS technology has successfully been demonstrated for the histological identification of ex-vivo breast tumor tissues, questions regarding the robustness of the approach and the possibility of tumor molecular diagnostics still remain unanswered. In the current study, we set out to determine whether it is possible to acquire cross-comparable REIMS datasets at multiple sites for the identification of breast tumors and subtypes.

Methods: A consortium of four sites with three of them having access to fresh surgical tissue samples performed tissue analysis using identical REIMS setups and protocols.

View Article and Find Full Text PDF

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.

JTO Clin Res Rep

August 2024

Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Introduction: Characteristics of long-term survivors in EGFR-mutant (EGFRm) NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors.

Methods: Clinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm metastatic NSCLC who started first-line therapy before 2015.

View Article and Find Full Text PDF
Article Synopsis
  • The 2016 and 2021 WHO classifications of CNS tumors have improved how we categorize IDH-mutant gliomas, leading to better treatment options and longer survival for patients.
  • Current treatment guidelines are still largely based on older data that mix different tumor types, often focusing on high-risk factors like age and residual tumor post-surgery.
  • New insights from recent studies suggest that postponing aggressive treatments like radiation and chemotherapy may be safe for many patients with lower-grade IDH-mutant gliomas, and that newer medications like vorasidenib could be beneficial before resorting to traditional therapies.
View Article and Find Full Text PDF